Adocia announces two new multi-hormonal combination projects
Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes
- BioChaperone® enables combinations of insulin lispro with pramlintide and insulin lispro with exenatide, three hormones approved for the treatment of diabetes.
- Medical benefit of such combinations already established in type 1 diabetes clinical trials with separate injections.
- New projects aim to offer more efficient therapy to people living with type 1 diabetes without increasing number of injections.
- First clinical study expected to start in Q4 2017.
Voir le communiqué de presse